Profile cover photo
Profile photo
Aethlon Medical, Inc.
30 followers -
Aethlon Medical, Inc. (NASDAQ:AEMD) is creating innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.
Aethlon Medical, Inc. (NASDAQ:AEMD) is creating innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.

30 followers
About
Aethlon Medical, Inc.'s posts

Post has attachment
Live Well highlights Aethlon's work with University of California Irvine Health studying patients with different kinds of cancer undergoing treatment to determine if there is a correlation between the level of exosome concentration in the blood and whether the treatment was working. Read the full article here:

Post has attachment
Aethlon announced today that Company Chairman and CEO, Jim Joyce will present at the 2017 BIO International Convention (BIO 2017) on June 21, 2017 at 11:15 AM Pacific Time. Mr. Joyce will present virus capture data from a recently concluded FDA-approved feasibility study that was designed to assess the safety of the Aethlon Hemopurifier® in health-compromised individuals infected with a viral pathogen. The presentation will be live audio webcast through a link available in the upcoming events section of the company's website.

Post has attachment
Aethlon CEO will be presenting an overview of the company's clinical strategy to combat infectious viral pathogens, including bioterror and pandemic threats that are not addressed with drug and vaccine therapies at today's LD Micro Invitational at 11:30AM PT. Mr. Joyce's presentation will be available through a live audio webcast on the Company website.

Post has attachment
Aethlon today announced CEO James Joyce will be a featured presenter at the LD Micro Invitational on Tuesday, June 6, 2017 at 11:30AM PT. A live audio webcast of Mr. Joyce's presentation will be available on the upcoming events section of the company's website.

Post has attachment
TIME's Brian Walsh explores factors contributing to America, and the world, being unprepared for emerging pandemic threats. Experts such as Bill Gates, World Health Organization Director Dr. Margaret Chan and former CDC Director Dr. Tom Frieden warn that nowhere near enough is being done to prepare, leaving the U.S. scarily exposed. Governments around the world are not prepared to deal with the next pandemic outbreak due to the lack of investments in new vaccines and technologies before the threat emerges. Read the full article, "The World Is Not Ready for the Next Pandemic," here:

Post has attachment
Aethlon today released a shareholder update authored by Chairman and CEO, Jim Joyce. In it, Mr. Joyce provides an update on steps taken following the conclusion of FDA-approved feasibility study of our Hemopurifier®. Aethlon plans to on leverage regulatory pathways that have recently emerged to accelerate the advancement of medical devices in the United States such as the FDA's Expedited Access Pathway (EAP) program. Read the full letter here:

Post has attachment
Aethlon disclosed today that an interview conducted with Company CEO Jim Joyce on the weekly Tech Nation radio program is available to be accessed online. The 27 minute interview begins at minute six of the program and ends at minute 33. Mr. Joyce discusses CTE and Exosome Sciences, Inc.'s upcoming clinical study of former NFL players and a data-supported biomarker candidate to detect and monitor Chronic Traumatic Encephalopathy (CTE) in living individuals. Access the interview here:

Post has attachment
Aethlon CEO spoke with Dr. Moira Gunn on NPR's Tech Nation to discuss Chronic Traumatic Encephalopathy (CTE) and plans for Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon, to initiate a clinical study of candidate blood test to detect CTE in former NFL players. Listen here:

Post has attachment
Aethlon announced today that the company has concluded an FDA-approved feasibility study designed to assess the safety of the Aethlon Hemopurifier® in health-compromised individuals. The single-site study was conducted at DaVita Med Center Dialysis in Houston, Texas. In the feasibility study, the Hemopurifier was observed to be well tolerated in End-Stage Renal Disease (ESRD) volunteers who were also infected with Hepatitis C virus (HCV). The inclusion of HCV-infected ESRD subjects served as a model to demonstrate virus reduction. No device-related adverse events were observed in enrolled subjects who met the study inclusion/exclusion criteria. Read today's press release for additional study details:

Post has attachment
Aethlon Medical Announces The Conclusion Of Hemopurifier Clinical Study
Wait while more posts are being loaded